GB0910032D0 - Use of serum composition to reduce the levels of TNF and/or VEGF in mammals - Google Patents

Use of serum composition to reduce the levels of TNF and/or VEGF in mammals

Info

Publication number
GB0910032D0
GB0910032D0 GBGB0910032.2A GB0910032A GB0910032D0 GB 0910032 D0 GB0910032 D0 GB 0910032D0 GB 0910032 A GB0910032 A GB 0910032A GB 0910032 D0 GB0910032 D0 GB 0910032D0
Authority
GB
United Kingdom
Prior art keywords
vegf
tnf
mammals
levels
reduce
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0910032.2A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aimsco Ltd
Original Assignee
Aimsco Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aimsco Ltd filed Critical Aimsco Ltd
Priority to GBGB0910032.2A priority Critical patent/GB0910032D0/en
Publication of GB0910032D0 publication Critical patent/GB0910032D0/en
Priority to PCT/GB2010/050977 priority patent/WO2010142997A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB0910032.2A 2009-06-11 2009-06-11 Use of serum composition to reduce the levels of TNF and/or VEGF in mammals Ceased GB0910032D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0910032.2A GB0910032D0 (en) 2009-06-11 2009-06-11 Use of serum composition to reduce the levels of TNF and/or VEGF in mammals
PCT/GB2010/050977 WO2010142997A1 (en) 2009-06-11 2010-06-10 Use of a serum composition to reduce the levels of tnf and/or vegf in mammals

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0910032.2A GB0910032D0 (en) 2009-06-11 2009-06-11 Use of serum composition to reduce the levels of TNF and/or VEGF in mammals

Publications (1)

Publication Number Publication Date
GB0910032D0 true GB0910032D0 (en) 2009-07-22

Family

ID=40937224

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0910032.2A Ceased GB0910032D0 (en) 2009-06-11 2009-06-11 Use of serum composition to reduce the levels of TNF and/or VEGF in mammals

Country Status (2)

Country Link
GB (1) GB0910032D0 (en)
WO (1) WO2010142997A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2781742A1 (en) 2013-01-17 2014-09-24 Danfoss A/S Shape memory alloy actuator for valve for refrigeration system
WO2015036986A2 (en) * 2013-09-16 2015-03-19 Prendergast Patrick T Wound fluid elevated protease enzyme inhibition through camelid blood products.
EP3156746B1 (en) 2015-10-14 2020-12-30 Danfoss A/S Expansion valve and vapour compression system

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003202093B2 (en) * 2001-07-02 2010-05-13 Aimsco Limited Treatment of MS with goat serum
EP2591822B1 (en) * 2004-04-05 2015-11-18 Aimsco Limited Treatment of diseases
CA2572777A1 (en) * 2004-07-08 2006-03-02 Aimsco Limited Medicament comprising corticotropin releasing factor and proopiomelanocortin, and uses thereof

Also Published As

Publication number Publication date
WO2010142997A1 (en) 2010-12-16

Similar Documents

Publication Publication Date Title
IL267138A (en) Improved cell composition and methods of making the same
BRPI1006441A2 (en) composite structure with one surface and overmolded composite structure
ZA201205683B (en) Probiotic composition for use in the treatment of bowel inflammation
IL219209A0 (en) Il-17 family cytokine compositions and uses
EP2432462A4 (en) Endoxifen methods and compositions in the treatment of mammalian diseases
PL2516497T3 (en) Composite materials comprising aggregate and an elastomeric composition
IL217389A0 (en) Methods and compositions for the recombinant biosynthesis of n-alkanes
EP2407508A4 (en) Resin composition and multilayered structure using the same
EP2554590A4 (en) Resin composition and multilayered structure using same
EP2511333A4 (en) Rubber composition and uses thereof
EP2275481A4 (en) Resin composition and multilayer structure using same
GB201117703D0 (en) Solid cosmetic composition with structurant and electrolyte solution
EP2491116A4 (en) Cell-based anti-cancer compositions and methods of making and using the same
EP2282648A4 (en) Prebiotic composition and methods of making and using the same
GB201005315D0 (en) Seperation and quantitation of the C3-epimer of 250HD3 in serum using UPLC/MS/MS
EP2415837A4 (en) Resin composition and multilayered structure
ZA201403592B (en) Composition for use in the promotion of magnesium absorption and/or magnesium retention
GB0910032D0 (en) Use of serum composition to reduce the levels of TNF and/or VEGF in mammals
PL2624859T3 (en) Factor ii alone or in combination with further factors for treatment of impaired haemostasis associated with dilutional coagulopathy
GB201004004D0 (en) Improvements in and relating to the consideration of evidence
EP2343199A4 (en) Rubber composite and rubber composition
GB2456130B (en) Improvements in and relating to the preparation of specimens
SI2291657T1 (en) Levels of blys/april heterotrimers in serum and use in diagnostic methods
GB0720400D0 (en) Improvements in or relating to the preparation of beverages
EP2257303A4 (en) Uses of modified elr-cxc chemokine g31p

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)